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Introduction
Cancer is one of the most common causes of death 
worldwide and accounted for 8.2 million deaths in 2012 
[1]. The number of cancer- related deaths is predicted to 
increase to over 11 million by 2030 [2]. The types of 
cancer with the highest incidence are lung (1.59 million 
people), liver (745,000), stomach (723,000), colon and 
rectum (694,000), breast (521,000), and esophagus 
(400,000) [1]. In oncology, the selection of correct treat-
ment strategy, in early disease stages, is crucial to increase 
the probability of remission and improve survival. Available 
cancer treatments include chemotherapy, immunotherapy 
or antibody- based therapy, radiation therapy, and surgery 
[3]. The therapeutic strategy is chosen taking into account 
the individual patient’s medical assessment, type of cancer, 
location, and disease stage [4]. Multimodal treatments are 
often required to reduce the therapy- induced side effects 
[5] related to pharmacological as well as other approaches 
including surgery [6]. Chemotherapy- induced side effects 
depend on various variables such as the drug employed, 
its dosage, and treatment duration. These side effects 
include pain, fatigue, throat and mouth sores, diarrhea, 
nausea, vomiting, constipation, and blood disorders. Side 
effects affecting the nervous system are commonly expe-
rienced with chemotherapy and include cognitive dysfunc-
tion, headache, dizziness, vision loss and vision disturbances 
such as blurred or double vision, changes in learning and 
memory, sexual dysfunction, ataxia, and peripheral neu-
ropathy [7–11]. Rashes, fever, hypotension, colitis or other 
gastrointestinal problems, and thyroid dysfunctions are 
immunotherapy- related side effects [12]. The main 
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Abstract
Cancer is one of the most common causes of death worldwide. Available treat-
ments are associated with numerous side effects and only a low percentage of 
patients achieve complete remission. Therefore, there is a strong need for new 
therapeutic strategies. In this regard, pulsed electromagnetic field (PEMF) therapy 
presents several potential advantages including non- invasiveness, safety, lack of 
toxicity for non- cancerous cells, and the possibility of being combined with other 
available therapies. Indeed, PEMF stimulation has already been used in the context 
of various cancer types including skin, breast, prostate, hepatocellular, lung, ovar-
ian, pancreatic, bladder, thyroid, and colon cancer in vitro and in vivo. At present, 
only limited application of PEMF in cancer has been documented in humans. 
In this article, we review the experimental and clinical evidence of PEMF therapy 
discussing future perspectives in its use in oncology.
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radiotherapy- induced side effects are dry mouth and gum 
sores, jaw stiffness, nausea, lymphedema, swallowing dif-
ficulties, shortness of breath, breast or nipple soreness, 
rectal bleeding, incontinence, bladder irritation, and pitui-
tary dysfunction [13]. Surgical techniques, such as mini-
mally invasive surgery, also result in pain, fatigue, appetite 
loss, swelling and bruising around the site of surgery, 
bleeding, infection, lymphedema, and organ dysfunction 
[14]. Numerous studies support the development of new 
treatments in oncology to be added to the traditional 
protocols to increase the effectiveness of available treat-
ments, reducing side effect profile, and the patients’ quality 
of life [15–18]. Such resources include traditional Chinese 
medicine, Ayurvedic medicine, homeopathy, and natur-
opathy [19]. While complementary and alternative medicine 
(CAM) is not generally considered part of conventional 
medicine, it has been widely used in the oncology field 
as an add- on therapy to control patients’ symptoms and 
improve their quality of life [20–26]. The beginning of 
the 20th century saw the first therapeutic applications of 
CAM therapies for cancer treatment; these therapies include 
acupuncture, chromotherapy, therapeutic touch (reiki), and 
pulsed electromagnetic field (PEMF) therapy [4, 15, 27–30]. 
In this review, we have focused on PEMF therapy, a non-
invasive technique characterized by electromagnetic fields 
inducing microcurrents to the entire body or locally to 
target specific body tissues. Exposure to PEMFs in the 
0–300 Hz range is a therapeutic tool extensively used for 
the treatment of several pathologies including osteoarthritis, 
Parkinson’s disease, postsurgical pain and edema, treatment 
of chronic wounds, and facilitation of vasodilatation and 
angiogenesis producing direct stimulation to excitable cells 
including nerve and muscle cells [31–34]. Stimulation with 
sufficient intensity and duration induces a current across 
targeted cell membranes, activating nerve cells or muscles 
to propagate action potentials [35–37]. Indeed, PEMF 
therapy can be used as an adjuvant treatment to chemo-
therapy and radiotherapy with the aim of reducing their 
dosage, mitigating any harmful secondary side effects, and 
enhancing patient’s prognosis [15, 35, 38–40].
Aim and searching criteria
We reviewed in vitro, in vivo, and clinical studies employ-
ing PEMF therapy for cancer treatment published between 
1976 and 2016. We searched Pubmed/Medline, Embase, 
Web of Science and Scopus using the keywords “PEMFs”, 
“cancer”, “magnet therapy”, “tumour specific frequen-
cies” and “oncology” alone or combined. This review 
aims at describing the state of the art of PEMF therapy, 
discussing current understanding of the underlying 
mechanisms and outlining future therapeutic perspectives 
in oncology.
In Vitro Studies
PEMF therapy has been extensively studied in vitro using 
various human cancer cell lines, such as 
pheochromocytoma- derived (PC12), breast cancer (e.g., 
MCF7, MDA- MB- 231 and T47D), and colon cancer (SW- 
480 and HCT- 116) [41–45]. These studies have shown 
that PEMF therapy may exert proliferative inhibition and 
mitotic spindle disruption [18, 40], block the development 
of neovascularization required for tumor supply [46–48] 
and exacerbate an inherent or induced genetic instability 
by reducing the stringency of the late- cycle (G2) checkpoint 
[49]. While chemotherapy is not specific to cancer cells 
and targets all rapidly dividing cells [50–52], PEMFs exert 
selective cytotoxic effect on neoplastic cells [15, 40, 53–55] 
making this therapy a highly promising strategy.
In the next subparagraphs, we will review studies employ-
ing PEMF therapy in different cell lines as a model to 
study specific types of cancer (Table 1).
Studies of PEMF therapy in human breast 
cancer and colon cancer cell lines
A study by Crocetti and coworkers [38] investigated whether 
ultra- low intensity and frequency PEMF therapy could induce 
apoptosis in human breast adenocarcinoma cells (MCF7). 
PEMF exposure was cytotoxic to MCF7 cells, but not to 
normal breast epithelial cells (MCF10). Both MCF7 and MCF10 
cells were exposed to PEMF therapy and the cytotoxic indices 
were measured in order to design PEMF paradigms that could 
reduce selectively neoplastic cell proliferation. The PEMF 
parameters tested were: (1) frequency of 20 Hz, (2) intensity 
of 3 mT and (3) exposure time of 60 min/day for up to 
3 days. Four independent methods of monitoring cancer- 
induced apoptosis (trypan blue assay, apoptosis determination 
by DNA strand break detection, analysis of cellular electrical 
properties by means of impedance microflow cytometer, and 
apoptosis determination by Annexin V staining) showed that 
this specific set of PEMF parameters was cytotoxic to breast 
cancer cells. While this treatment selectively induced apoptosis 
of MCF7 cells, it had no effect on MCF10 cells that were 
more resistant to apoptosis in response to PEMFs. Although 
these results are encouraging, PEMF exposure was limited to 
3 days. Long- term PEMF exposure needs to be assessed in 
further studies based on the concept that PEMF effectiveness 
is strictly linked to the signal parameters, exposure magnitude, 
duration, signal shape, duration of treatment as well as the 
type of cells exposed to the magnetic field [56, 57].
The antineoplastic effect of PEMFs has also been inves-
tigated in human breast cancer MDA- MB- 231, colon cancer 
SW- 480, and HCT- 116 cell lines. These cells were exposed 
to 50 Hz PEMFs for 24 and 72 h [58]. PEMFs decreased 
the number of viable cells in all the cell lines tested, 
3130 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
M. Vadalà et al.PEMFs in Oncology
reaching 55% after 24 h and 20% after 72 h in the MDA- 
MB- 231 cell line, 11% after 24 h and 6% after 72 h in the 
SW480 cell line, and 2% after 24 h and 3% after 72 h in 
the HCT- 116 cell line, compared with unexposed cancer 
cell lines used as controls, as assessed by a computer reaction- 
diffusion model, a mathematical model widely employed to 
study cell proliferation and infiltration [59]. The lower per-
centage inhibition of neoplastic cell proliferation was observed 
after 72 h, showing that PEMF therapy had antiproliferative 
activity which decreased over time. This action is exerted 
in vitro by interfering with microtubule spindle polymeriza-
tion. Indeed, PEMF exposure reduces the fraction of polym-
erized microtubules, disrupts the mitotic spindle structure, 
inhibits cell division, thereby leading to chromosome mis- 
segregation and cancer- induced apoptosis [60]. In summary, 
studies in human breast and colon cancer cell lines are 
promising and warrant further investigations.
Studies of PEMF therapy in 
pheochromocytoma- derived cells
PEMF signal parameters have been extensively utilized on 
diverse cell types to determine in vitro effectiveness [61, 62]. 
For example, Morabito and coworkers [41] investigated 
cell responsiveness and in vitro neuritogenesis following 
PEMF exposure. They specifically focused on PEMF ability 
to modify morphology, proliferation, and differentiation in 
PC12 pheochromocytoma cells. Furthermore, they assessed 
whether PEMFs can induce variable and species- specific 
alterations in the oxidative stress pathway such as Ca2+- 
dependent oxidative stress which enhances free radical 
production, particularly via the Fenton reaction, leading 
to apoptotic cell death [63–69]. Undifferentiated and dif-
ferentiated [supplemented with 50 ng/mL of nerve growth 
factor (NGF)] PC12 cells were exposed to 50 Hz PEMF 
therapy (0.1–1.0 mT), and cell growth and viability were 
evaluated after immediate (30 min) or long- term exposure 
(7 days), using colorimetric and morphological assays. The 
long- lasting exposure to PEMFs did not affect the biological 
response in terms of proliferation and neuritogenesis. Thirty- 
minute PEMF exposure at 1.0 mT in undifferentiated PC12 
cells increased the levels of reactive oxygen species (ROS) 
and decreased catalase activity, an indicator of oxidative 
stress. Conversely, long- term PEMF exposure of undiffer-
entiated PC12 cells also increased catalase activity that could 
reflect the absence of ROS accumulation and a possible 
adaptation cell response to PEMFs. During immediate PEMF 
exposure in undifferentiated PC12 cells, no change in intra-
cellular Ca2+ concentration was observed, while it increased 
after long- term exposure. This enhanced calcium level could 
activate, through voltage- gated (L- type) calcium channels, 
signaling pathways and lead to the expression of genes 
modulating cell differentiation, survival, and apoptosis such 
as extracellular signal- regulated kinases, c- Jun N- terminal 
protein kinase/stress- activated protein kinase, and p38 
[70–73]. In particular, the undifferentiated PC12 cells were 
more sensitive to PEMFs exposure, while the differentiated 
PC12 cells were more stable and resistant to stress, 
Table 1. In vitro studies of PEMF therapy in oncology.
Author(s), year Cell type Treatment Main findings References
Crocetti et al., 2013 Human breast adenocarci-
noma cells (MCF7) and 
nontumorigenic cells (MCF10)
Daily 60- min PEMF therapy 
session (20 Hz; 3 mT) for 
3 days
PEMFs increased apoptosis in MCF7 
cells but had no effect on MCF10 
cells
[38]
Filipovic et al., 2014 Human breast cancer 
(MDA- MB- 231) and colon 
cancer (SW- 480 and 
HCT- 116) cell lines
24 and 72 h exposure to 
PEMF therapy (50 Hz; 
10 mT)
PEMFs increased apoptosis in 
MDA- MB- 231 (55% and 20%), 
SW480 (11% and 6%), and HCT- 116 
cell lines (2% and 3%) after 24 and 
72 h exposure, respectively, 
compared with untreated control 
cancer cell lines
[58]
Morabito et al., 2010 Undifferentiated PC12 
pheochromocytoma cells and 
differentiated PC12 cells
Short PEMF therapy session 
(50 Hz, 0.1–1.0 mT) for 
30 min, and long- term 
PEMF session (50 Hz, 
0.1–1.0 mT) for 7 days
30- min PEMF session in undifferenti-
ated PC12 cells increased ROS levels 
and decreased catalase activity. No 
change in intracellular Ca2+ 
concentration was observed. 7- day 
PEMF therapy session in undifferenti-
ated PC12 cells resulted in increased 
intracellular Ca2+ concentration and 
increased catalase activity. No 
significant findings were observed in 
differentiated PC12 cells
[41]
PEMF, pulsed electromagnetic field; ROS, reactive oxygen species.
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probably due to the action of the cell surface NGF recep-
tors such as p75NR [74].
Further studies are necessary to identify the ROS/intra-
cellular Ca2+ cross- talking pathway activated by PEMF 
therapy. However, the study by Morabito and coworkers 
supports the hypothesis that ROS and Ca2+ could be the 
cellular “primum movens” of PEMF therapy- induced 
effects, as observed in pheochromocytoma cells.
In Vivo Studies
Several studies investigated the antineoplastic effect of 
PEMFs using widely employed animal models of several 
types of cancer, including breast cancer, hepatocellular 
carcinoma (HCC), and melanoma (Table 2) [4, 48, 75–78].
PEMF therapy effectiveness in mouse 
models of breast cancer
PEMF therapy effectiveness on tumor growth and viability 
has been tested in mouse models of breast cancer. For 
example, xenograft mouse models are widely used to study 
breast cancer. This model is obtained by injection of human 
breast cancer cells including estrogen- negative (MDA- 
MB- 231) and estrogen- positive (MCF7) breast carcinoma 
cell lines or mouse breast cancer cells including EpH4 mam-
mary epithelial cells or mitogen- activated protein kinase 
(MEK)- transformed EpH4 cells subcutaneously, intrave-
nously, intracardially, or orthotopically, four times every 
5 days, into the mammary fat pad of immunocompromised 
mice [79, 80]. The injected cells are highly invasive in vitro 
and tumorigenic when transplanted into the mammary fat 
pad. After a week from the last injection, the mouse is 
palpated biweekly for mammary tumors and the dimensions 
of tumors are measured using an external caliper daily. 
Mice are euthanized when the tumor size becomes ulcerated 
with macro- metastases, mainly in liver, bone, and brain 
[81–84]. For example, EpH4-MEK Bcl213 cells (1 × 106) 
transfected with a luciferase expression vector (pβP2- PolII- 
luciferase) were injected into the mammary fat pad in 12 
T- cell- immunodeficient Swiss outbred female nude mice 
(Cr:NIH(S)- nu/nu) [85]. Mice were divided into four groups 
(n = 3 each). Group 1, 2, and 3 were exposed to PEMF 
therapy (1 Hz, 100 mT) daily for 60, 180, or 360 min, 
respectively, for 4 weeks, while group 4 did not receive 
PEMF therapy and was used as control. All mice were 
monitored for tumor growth by body bioluminescence imag-
ing once every 2 to 4 days for 4 weeks. Then, all the mice 
were sacrificed and skin, liver, lung, and spleen samples 
were collected for histopathologic analysis. Mice exposed to 
PEMFs for 60 and 180 min daily showed a 30% and 70% 
breast tumor reduction, respectively, at week 4, if compared 
to baseline. Mice exposed to PEMFs for 360 min daily, 
showed a suppression of tumor growth at week 4. In sum-
mary, this study shows that the time of PEMF exposure is 
critical to determine its effectiveness. Mice exposed for longer 
duration (360 min daily for 4 weeks) showed a significant 
reduction in tumor size, due probabily to the inhibition of 
angiogenesis that may suppress the formation of blood ves-
sels in tumor tissues, reducing the tumor growth.
Antineoplastic effect of PEMF therapy in 
rodent models of hepatocellular carcinoma
Chemically induced HCC is a widely used model of 
hepatocarcinogenesis that mimics the development of 
fibrosis and cirrhosis. This model is obtained by intra-
peritoneal administration of a carcinogenic agent, 
N- diethylnitrosamine (DEN; 50–100 mg/kg mouse body 
weight) alone or followed by oral administration of a 
nongenotoxic liver tumor promoter [phenobarbital (PB)]. 
DEN induces damage to DNA, proteins, and lipids, lead-
ing to hepatocyte death [86]. It is hydroxylated to α- 
hydroxylnitrosamine, mediated by cytochrome P450 
enzymes which are primarily located in the centrilobural 
hepatocytes. Then, an electrophilic ethyldiazonium ion 
is formed and causes DNA damage by reacting with 
nucleophiles. Three to four weeks following the last 
injection, mice receive drinking water containing PB 
(0.07%) that increases the expression of cytochrome P450, 
inducing oxidative stress and resulting in HCC develop-
ment after 6 months from PB administration [86–90]. 
Emara and coworkers evaluated the safety and effective-
ness of PEMFs with different intensity and frequency in 
a rat model of DEN- induced HCC (75 mg/kg body 
weight, once a week for 3 weeks) [91]. Sixty rats were 
divided into six groups: Group 1 (naive rats) received 
PEMF therapy (2-3 Hz, 0.004 T) for 30 min/day for 6 
days/week for 4 weeks; group 2 (naive rats) received 
PEMF therapy (<1 Hz, 0.6 T) 15 min/day for 6 days/
week for 4 weeks; group 3 (naive rats) was left untreated; 
group 4 (HCC rats) received PEMF therapy (2-3 Hz, 
0.004 T) for 30 min/day for 6 days/week for 4 weeks; 
group 5 (HCC rats) received PEMF therapy (<1 Hz, 
0.6 T) 15 min/day for 6 days/week for 4 weeks; group 
6 (HCC rats) was left untreated. No changes in histo-
pathology and dielectric properties of liver tissue were 
observed in naive rats exposed to PEMFs supporting its 
safety.  In HCC rats exposed to PEMFs, a significant 
decrease in AFP level (AFP is a serum glycoprotein often 
elevated in HCC patients and used as a carcinoma marker 
in the clinic) was reported together with a slight improve-
ment in dielectric properties of liver tissue. These results 
were confirmed by electron microscopy and histological 
analysis showing HCC regression. Altogether this evidence 
supports the antineoplastic activity of PEMF therapy in 
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the rat model of DEN-induced HCC and warrants further 
investigations. 
PEMF therapy effectiveness in murine 
melanoma models
The most frequently used murine melanoma model is the 
syngeneic B16 model. It is obtained by a single subcutane-
ous injection of 1 × 105 B16 murine melanoma cells on 
the dorsal side of the mouse ear. Melanoma nodules 
5–6 mm in diameter develop 7 days post- injection [92–94]. 
The melanoma model in SKH- 1 hairless mice has been 
used to investigate the effectiveness of PEMF therapy 
(0.5 Hz, 0.2 T, 30 min/day). Mice (n = 23) received 1–3 
PEMF treatments daily for 6 days and were monitored 
for tumor growth, daily, by optical methods, such as tran-
sillumination and power Doppler ultrasound reconstruc-
tions that display blood flow images for each tumor [95]. 
Table 2. In vivo studies of PEMF therapy in oncology.
Author(s), 
year
Animal model (number 
of animals, study design)
Route of 
administration Treatment Main findings References
Tatarov 
et al., 2011
12 T- cell- 
immunodeficient 
Swiss outbred female 
nude mice (Cr:NIH(S)- 
nu/nu), divided into 4 
groups (n = 3 each)
Orthotopic injection 
of metastatic 
mouse breast 
tumor cell line 
[EpH4-MEK Bcl213 
cells (1 × 106)] 
into the mammary 
fat pad
Group 1, 2 and 3 were 
exposed to PEMFs (1 Hz, 
100 mT) daily for 60, 180, or 
360 min, respectively, for 
4 weeks; group 4 did not 
receive any treatment and 
was used as control
Mice exposed for 60 and 
180 min daily showed a 
30% and 70% tumor 
reduction, respectively, at 
week 4, if compared to 
baseline
[85]
Emara  
et al., 2013
60 rats (strain not 
reported) divided into 
6 groups
Intraperitoneal 
administration of 
a carcinogenic 
agent, DEN
Group 1 (naive rats) received 
PEMF therapy (2-3 Hz, 0.004 
T) for 30 min/day for 6 days/
week for 4 weeks; group 2 
(naive rats) received PEMF 
therapy (<1 Hz, 0.6 T) 15 
min/day for 6 days/week for 
4 weeks; group 3 (naive 
rats) was left untreated; 
group 4 (HCC rats) received 
PEMF therapy (2-3 Hz, 0.004 
T) for 30 min/day for 6 days/
week for 4 weeks; group 5 
(HCC rats) received PEMF 
therapy (<1 Hz, 0.6 T) 15 
min/day for 6 days/week for 
4 weeks; group 6 (HCC rats) 
was left untreated.
A significant decrease in 
serum AFP level and a slight 
improvement in dielectric 
properties of liver tissues 
was observed in HCC rats 
treated with PEMFs. These 
results were confirmed by 
electron microscopy and 
histological analysis showing 
HCC regression. No changes 
in histopathology and 
dielectric properties of liver 
tissue were observed in 
naive rats exposed to 
PEMFs.
[91]
Nuccitelli 
et al., 2006
23 SKH- 1 immunocom-
petent, hairless, albino 
mice
Single subcutane-
ous injection of 
B16 murine 
melanoma cells 
(1 × 105) on the 
dorsal side of the 
mouse ear
30- min PEMF therapy session 
(0.5 Hz, 0.2 T) three times a 
day for 6 days
All mice exhibited significant 
pyknosis, shrinkage of the 
tumor cell nuclei by 54% 
within a few minutes after 
PEMF therapy and by 68% 
within 3 h and reduction in 
the blood flow in about 
15 min following PEMF 
therapy
[95]
Nuccitelli 
et al., 2010
Four female immuno-
deficient, hairless, 
albino Nu/Nu mice
Single subcutane-
ous injection of 
murine melanoma 
cells (B16- F10- 
eGFP, 1 × 105) on 
the mouse skin
Daily 6- min PEMF session 
(5–7 Hz, 0.2 T) for 10 days
Melanoma cells shrank within 
an hour post PEMF therapy, 
exhibiting pyknosis within 
24 h post treatment. 
PEMFs- treated mice showed 
complete remission of 
melanoma
[100]
PEMF, pulsed electromagnetic field; DEN, N- diethylnitrosamine; AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma
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Then, all the mice were sacrificed and skin tissues were 
collected for histopathological analysis. All mice exposed 
to PEMFs exhibited significant pyknosis, shrinkage of the 
tumor cell nuclei by 54% within a few minutes after PEMF 
therapy and by 68% within 3 h and reduction in the 
blood flow in about 15 min following PEMF therapy. 
These effects may be due to PEMF therapy that stimulates 
murine melanoma to self- destruct by triggering rapid pyk-
nosis of tumor cell nuclei and reducing blood flow [96–99]. 
A further study [100] optimized the PEMF therapy param-
eters pulse number, amplitude, and frequency to completely 
suppress melanoma with a single treatment. In this study, 
four female immunodeficient, hairless, albino Nu/Nu mice 
received a single PEMF treatment for 6 min using the 
following parameters: 2.700 pulses, amplitude of 30 kV/
cm and frequency of 5–7 Hz for 10 days. After 2–4 weeks, 
mice were sacrificed and skin samples were processed for 
histology. Melanoma cells shrank within an hour post 
PEMF therapy, exhibiting pyknosis within 24 h post PEMFs 
and showing a complete remission of melanoma in all 
the mice, as assessed by in vivo imaging (transillumination 
and photography). To evaluate the safety of PEMF therapy, 
the authors recorded the physiological parameters and 
introduced a miniature thermocouple into the tumor for 
simultaneous measurement of intratumoral temperature 
during PEMF treatment; body temperature and systolic 
blood pressure showed no significant changes, while the 
intratumoral temperature was ~6–7°C, evidencing that, by 
limiting the frequency to 7 Hz or less, it was possible to 
avoid heating the tumor to hyperthermia temperatures 
potentially leading to damage of the surrounding tissues. 
Evidence of efficacy of a single PEMF treatment on mouse 
skin cancer resulting in suppression of tumor growth and 
induction of apoptosis is promising for translational 
applications.
Clinical Studies
The use of PEMF therapy in oncology is still limited 
(Table 3) [4]. The first study utilizing PEMF therapy was 
conducted by Barbault and coworkers who hypothesized 
that a combination of specific frequencies, defined tumor- 
specific frequencies, may display therapeutic effectiveness 
for localized treatment of tumors [15]. They identified a 
total of 1524 tumor- specific frequencies, ranging from 0.1 
to 114 kHz, consisting in the measurement of variations 
in skin electrical resistance, pulse amplitude, and blood 
pressure in 163 patients affected by different types of cancer 
including brain tumors, colorectal cancer, HCC carcinoma, 
pancreatic, colorectal, ovarian, breast, prostate, lung, thy-
roid, and bladder cancer and exposed to the radiofrequency 
system. Self- administered PEMF therapy for 60 min, three 
times a day, for an average of 278.4 months was offered 
to only 28 patients with advanced cancer (breast cancer 
[n = 7], ovarian cancer [n = 5], pancreatic cancer [n = 3], 
colorectal cancer [n = 2], prostate cancer [n = 2], glio-
blastoma multiforme [n = 1], HCC carcinoma [n = 1], 
mesothelioma [n = 1], neuroendocrine tumor [n = 1], 
non- small- cell lung cancer [n = 1], oligodendroglioma 
[n = 1], small- cell lung cancer [n = 1], sarcoma [n = 1] 
and thyroid tumor [n = 1]). None of the patients who 
received PEMF therapy reported any side effects; four 
patients presented stable disease for 3 years (thyroid cancer 
with biopsy- proven lung metastases), 6 months (mesothe-
lioma metastatic to the abdomen), 5 months (non- small- cell 
lung cancer), and 4 months (pancreatic cancer with biopsy- 
proven liver metastases), respectively.
PEMF therapy has also been employed for the treat-
ment of HCC. Therapies for this disease are needed, 
especially for patients at an advanced disease stage who 
cannot tolerate chemotherapy or intrahepatic interventions 
because of impaired liver function [101]. The feasibility 
of PEMF therapy for treatment of HCC has also been 
investigated in a single- group, open- label, phase I/II clini-
cal study [102]. Forty- one patients with advanced HCC 
received very low levels of PEMFs modulated at HCC- 
specific frequencies (100 Hz–21 kHz) and received three- 
daily 60 min outpatient treatments. No adverse reactions 
were observed during PEMF treatment. Five patients 
reported complete disappearance and two patients reported 
decrease in pain shortly after beginning of treatment. Four 
patients showed a partial response to treatment, while 16 
patients (39%) had stable disease for more than 12 weeks. 
This study shows that PEMF therapy provides a safe and 
well- tolerated treatment, as well as evidence of antineo-
plastic effects in patients with HCC.
In summary, encouraging findings warrant randomized 
clinical studies to determine the effectiveness of amplitude- 
modulated PEMF therapy that can delay cancer progression 
and increase overall survival in patients. The increased 
knowledge of tumor- specific frequencies and the prelimi-
nary evidence that additional tumor- specific frequencies 
may yield a therapeutic benefit provide a strong rationale 
for the novel concept that administration of a large num-
ber of these frequencies may result in successful long- term 
disease management.
Discussion and Conclusions
In vitro studies support antineoplastic and antiangiogenic 
effects of PEMF therapy. Several mechanisms of PEMF 
therapy have been elucidated. For example, PEMFs inhibit 
cancer growth by disrupting the mitotic spindle in a pro-
cess mediated by interference of spindle tubulin orientation 
and induction of dielectrophoresis. Furthermore, PEMF 
therapy modulates gene expression and protein synthesis 
3134 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
M. Vadalà et al.PEMFs in Oncology
interacting with specific DNA sequences within gene pro-
moter regions [18, 38, 40, 41, 58, 103]. In addition, PEMFs 
inhibit angiogenesis in tumor tissues, suppressing tumor 
vascularization and reducing tumor growth, as shown by 
in vivo studies [95-99, 104].
The specific claim, supported by the described in vivo 
studies, is that all treated groups showed slower tumor 
growth rate if compared with untreated control group, 
confirming that PEMF therapy can modulate the physiol-
ogy and electrochemistry of cancer cells and influence 
cell membrane systems and mitosis. In addition, PEMFs 
induce some changes in membrane transport capacity 
through impacting the osmotic potential, ionic valves and 
leading to reduction in cellular stress factors, increase in 
the rate of DNA transcription, and modulation of immune 
response [105].
PEMFs have also an immunomodulatory effect, as sup-
ported by in vivo evidence showing an increase in tumor 
necrosis factor alpha levels that induce an anti- tumoral 
response, leading to the activation of a proapoptotic path-
way induced by caspase- 8 interaction with Fas- associated 
death domain, in the spleen of the murine melanoma 
mouse model after a 16-day therapy [78]. Changes in 
blood pressure, skin electrical resistance, and pulse ampli-
tude in 163 oncology patients exposed to tumor- specific 
PEMF frequencies have also been reported suggesting that 
PEMF therapy does not only target neoplastic cells, but 
may also have systemic effects [15]. However, long- term 
PEMF treatment in HCC patients is not toxic, confirming 
the safety of PEMF therapy that employs 100,000 times 
lower frequencies if compared with radiofrequency abla-
tion that is also employed for treatment of HCC [55].
Table 3. Clinical studies of PEMF therapy in oncology.
Author(s), 
year Study design
Number 
of 
patients Pathology Treatment Outcomes
Side 
effects References
Barbault 
et al., 2009
Compassionate 
and 
investigational 
clinical trial
28 Glioblastoma 
multiforme, 
mesothelioma, 
oligodendroglioma, 
sarcoma, HCC and 
breast, colorectal, 
lung, neuroendo-
crine, ovarian, 
pancreatic, 
prostate and 
thyroid cancers
60- min PEMF 
session 
(0.1 Hz–
114 kHz, 1.5 T) 
three times a 
day for 
278.4 months
One patient with 
thyroid cancer, one 
patient with 
mesothelioma 
metastatic to the 
abdomen, one 
patient with 
non- small- cell lung 
cancer and one 
patient with 
pancreatic cancer 
with biopsy- proven 
liver metastases 
presented stable 
disease for 3 years, 
6 months, 
5 months and 
4 months, 
respectively
None 
reported
[15]
Costa et al., 
2007
A single- group, 
open- label, 
phase I/II 
clinical trial
41 Advanced HCC Daily 60- min 
PEMF session 
(100 Hz–
21 kHz, 1.5 T) 
three times a 
day for 
6 months
Five patients 
reported complete 
disappearance and 
two patients 
reported decrease 
in pain shortly after 
treatment. Four 
patients showed a 
partial response to 
treatment, while 16 
patients had stable 
disease for more 
than 12 weeks
None 
reported
[102]
PEMF, pulsed electromagnetic field; HCC, hepatocellular carcinoma.
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In conclusion, only two clinical studies have used 
PEMF therapy for cancer treatment. These studies show 
that PEMF therapy is safe and promising compared to 
other available cancer therapies. In the future, PEMFs 
could be used not only as primary therapy but also in 
combination with other common antineoplastic therapies. 
Given that new portable and affordable PEMF devices 
are increasingly available on the market, future controlled 
clinical studies are expected to further determine the 
potential of PEMF therapy in oncology.
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